At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
Atrasentandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Single-Arm Study of the Effects of Atrasentan on Spermatogenesis and Testicular Function
In Brief
A Phase 2 clinical trial evaluating Atrasentan for Nephropathy and Diabetes. Completed, enrolled 20 participants across 13 sites in 4 countries.
Detailed Summary
This study is being conducted to evaluate the effects of Atrasentan on sperm production and testicular function in male subjects with Type 1 or 2 Diabetes and Nephropathy. This study included 2 periods: a Treatment Period (up to 26 weeks) followed by an Observational Period (up to an additional 52 weeks).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNephropathy, Diabetes
CountriesGermany, Italy, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 2014
Enrollment StartApr 2015
Primary CompletionApr 2018
Study CompletionJul 2018
TodayJul 2026
First PostedApr 21, 2014
Enrollment StartApr 6, 2015
Primary CompletionApr 18, 2018
Study CompletionJul 16, 2018
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 12.2 years ago
Interventions
Atrasentandrug
Atrasentan